

ISSN 1820-0254



The New
**ARMENIAN MEDICAL
JOURNAL**

Vol.14 No 4 December 2020

OFFICIAL PUBLICATION OF THE YEREVAN STATE MEDICAL UNIVERSITY

YEREVAN



OFFICIAL PUBLICATION
OF YEREVAN STATE MEDICAL UNIVERSITY



THE NEW

ARMENIAN MEDICAL

JOURNAL

Volume 14, Number 4, December 2020



*To overcome it
is possible, due to the
uniting the knowledge and
will of all doctors in the world*



Our home page on Internet
www.ysmu.am

Y E R E V A N



The Journal is founded by
Yerevan State Medical
University after M. Heratsi.

Rector of YSMU

Armen A. Muradyan

Address for correspondence:

Yerevan State Medical University
2 Koryun Street, Yerevan 0025,
Republic of Armenia

Phones:

(+37410) 582532 YSMU

(+37410) 580840 Editor-in-Chief

Fax: (+37410) 582532

E-mail: namj.ysmu@gmail.com, ysmi@mail.ru

URL: <http://www.ysmu.am>

*Our journal is registered in the databased, EBSCO
and Thomson Reuters (in the registration process)*



SCOPUS



EBSCO



THOMSON
REUTERS

Copy editors: Tatevik R. Movsisyan

Printed in SP "MOA" LLC
Director: L. Lalayan
Address: Armenia, 0033, Yerevan,
Gyulbekyan St., Building 39
Phone: (+374 94) 444 802,
E-mail: mosspsy@mail.ru

Editor-in-Chief

Arto V. **Zilfyan** (Yerevan, Armenia)

Deputy Editors

Hovhannes M. **Manvelyan** (Yerevan, Armenia)

Hamayak S. **Sisakyan** (Yerevan, Armenia)

Executive Secretary

Stepan A. **Avagyan** (Yerevan, Armenia)

Editorial Board

Armen A. **Muradyan** (Yerevan, Armenia)

Drastamat N. **Khudaverdyan** (Yerevan, Armenia)

Levon M. **Mkrtchyan** (Yerevan, Armenia)

Foregin Members of the Editorial Board

Carsten N. **GUTT** (Memmingen, Germany)

Muhammad **MIFTAHUSSURUR** (Surabaya, Indonesia)

Alexander **WOODMAN** (Dharhan, Saudi Arabia)

Edita **MARGARYAN** (MOSCOW, RUSSIA)

Coordinating Editor (for this number)

Muhammad **Miftahussurur** (Surabaya, Indonesia)

Editorial Advisory Council

Ara S. **Babloyan** (Yerevan, Armenia)

Aram **Chobanian** (Boston, USA)

Luciana **Dini** (Lecce, Italy)

Ruben V. **Fanarjyan** (Yerevan, Armenia)

Gerasimos **Filippatos** (Athens, Greece)

Gabriele **Fragasso** (Milan, Italy)

Samvel G. **Galstyan** (Yerevan, Armenia)

Edita G. **MARGARYAN** (MOSCOW, RUSSIA)

Arthur A. **GRIGORIAN** (Macon, Georgia, USA)

Armen Dz. **Hambardzumyan** (Yerevan, Armenia)

Seyran P. **Kocharyan** (Yerevan, Armenia)

Aleksandr S. **Malayan** (Yerevan, Armenia)

Mikhail Z. **Narimanyan** (Yerevan, Armenia)

Levon N. **Nazarian** (Philadelphia, USA)

Linda F. **Noble-Haeusslein** (San Francisco, USA)

Eduard S. **Sekoyan** (Yerevan, Armenia)

Arthur K. **SHUKURYAN** (Yerevan, Armenia)

Suren A. **STEPANYAN** (Yerevan, Armenia)

Hakob V. **Topchyan** (Yerevan, Armenia)

Armen A. **Trchunyan** (Yerevan, Armenia)

Alexander **Tsiskaridze** (Tbilisi, Georgia)

Konstantin B. **Yenkoyan** (Yerevan, Armenia)



CONTENTS

4. **ZILFYAN A.V., AVAGYAN S.A., MURADYAN A.A., GHAZARYAN V.J., GHAZARYAN H.V.**
POSSIBLE ROLE OF ALIPHATIC POLYAMINES IN THE INHIBITION PROCESS OF DAUGHTER VIRUSES REPLICATION IN COVID-19 INFECTION. EXPEDIENCY OF ADDING -DIFLUOROMETHYLORNITHINE TO THE REGISTRY OF DRUGS FOR COVID-19 INFECTION
16. **ADRIANA D.N., MIFTAHUSSURUR M.**
CURRENT STRATEGY TO COMBAT COVID-19 IN INDONESIA
29. **ASMARAWATI T.P., ARFIJANTO M.V., HADI U, MIFTAHUSSURUR M.**
HEALTHCARE ASSOCIATED COVID-19 TRANSMISSION: STRATEGIES TO PREVENT
37. **WOODMAN A., AL JAMEA L., JEBAKUMAR A.Z.**
GROWING TRENDS AND TRANSMISSION DYNAMICS OF NOVEL CORONAVIRUS – COVID 19
43. **MAHMUDAH I., WASKITO L.A., MIFTAHUSSURUR M.**
FREQUENTLY ASKED QUESTIONS OF NOVEL CORONAVIRUS: A REVIEW OF THE EVIDENCE
56. **TAJIBAYEV T.K., SAGATOV I.Y.*, BEKMUHAMEDOVA A.Y., MEDEUBEKOV U.S., BAIMAKHANOV B.B.**
ANTIBODY RESPONSE TO SARS-COV-2 WITHIN HEALTHCARE WORKERS: A SINGLE-CENTER STUDY IN KAZAKHSTAN
59. **SOEGIARTO G.**
VACCINATION FOR CORONAVIRUS DISEASE 2019: OPPORTUNITY, HOPE AND CHALLENGES
70. **SUGIHARTONO T.¹, ARAFAH N.¹, YAMAOKA^{1,2}, MIFTAHUSSURUR M.^{1,2*}**
GASTROINTESTINAL MANIFESTATIONS IN COVID-19 INFECTION
82. **PRAJITNO J.N., SUSANTO H., SOELISTIJO S.A.***
PHYSICAL INACTIVITY AND ANXIETY WITH CARDIOMETABOLIC RISK FACTOR IN TYPE 2 DIABETES MELLITUS PATIENTS DURING CORONAVIRUS DISEASE 2019 PANDEMIC
88. **NAVASARDYAN L.V., MARKOSYAN R.L.**
DIABETES CARE PECULIARITIES AND MANAGEMENT DURING COVID-19 PANDEMIC: A REVIEW OF CURRENT GUIDELINES
91. **BUDIARTI R, DIARSVITRI W., RACHMAN B.E., SUGIHARTONO T, YAMAOKA Y, MIFTAHUSSURUR M.**
THE SURGE OF DENGUE CASES DURING COVID-19 IN INDONESIA
100. **BASUKI W., PRAMUDYA D., ADIWINOTO R.D.**
CYCLOSPORINE A IMPROVES OUTCOME OF KIDNEY TRANSPLANT RECIPIENTS WITH CORONAVIRUS DISEASE 2019: A META-ANALYSIS
107. **KURKATOVA S.O., MAKEEVA I.M., MARGARYAN E.G., DIKOPOVA N.ZH., VOLKOV A.G., MODINA S.V., SAMOKHLIB Y.V.**
FEATURES OF THE COVID-19 CLINICAL COURSE IN DOCTORS IN THE FAMILY CLUSTER OF INFECTION. DESCRIPTION OF A CLINICAL CASE
114. **AVAGYAN S.A., ZILFYAN A.V., MURADYAN A.A., GHAZARYAN V.J., GHAZARYAN H.V.**
NEW PERSPECTIVES FOR THE PREVENTION TAND REATMENT OF CORONAVIRUS INFECTION COVID-19. THE ROLE OF POLYAMINE DEPENDENT MECHANISMS OF THE LIFE CICLE OF RNA AND DNA VIRUSES IN MAMALIANS



VACCINATION FOR CORONAVIRUS DISEASE 2019: OPPORTUNITY, HOPE AND CHALLENGES

SOEGIARTO G.

Allergy and Clinical Immunology Division, Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Received 22.04.2020; accepted for printing 14.07.2020

Abstract

COVID-19 continues to become a global threat. The development of COVID-19 vaccine has a potential to induce long-lasting cellular and humoral immunity and ending this pandemic. Currently, there are 213 vaccines in development, with 66 in clinical trials and 9 in phase III. In one hand the vaccines are developed using novel vaccine platforms including DNA and mRNA based, antigen-presenting cell, viral vector, protein or peptide-based, inactivated virus, and live attenuated virus platform. Each of these platforms has its own strength and weakness; however, they generally enable the vaccine to be developed safely, more quickly, and easier to upscale. In the other hand, the demand for COVID-19 vaccine has led to the development of vaccine being fast-tracked. Concerns are being raised for the efficacy, safety, equitability, and acceptance of these vaccines. Many are worried about the possibility of antibody-dependent enhancement that may worsen the recipient's condition. Vaccine design therefore should take into account previous experience with vaccine-associated disease enhancement. Researchers should adhere to stringent standards of safety and efficacy when conducting vaccine's clinical trials. Accelerated trials should also adhere to the Declaration of Helsinki for the ethics of medical research. Global partnership for vaccine development and equitable distribution is also needed to prevent resurgences of cases. Finally, there is a need to combat misinformation and distrust of COVID-19 vaccine in the eye of the general public.

KEYWORDS: SARS-CoV-2, COVID-19, vaccine, safety, efficacy.

INTRODUCTION

Since its discovery in late 2019, SARS-CoV-2 infection has spread into the whole world. Until the writing of this review, there have been over 42 million cases, with more than and over 1.1 million deaths attributed to COVID-19 [WHO, 2020a]. So far, the five countries with most cases of COVID-19 are The United States of America, India, Brazil, Russian Federation, and Argentina. Meanwhile, Indonesia sits at the 17th place with around 380 thousand total cases with more than 13 thousand deaths [WHO, 2020c].

This unprecedented disaster has driven many countries to look for cure by repurposing older antiviral and parasitocidal drugs. Currently, there aren't

any drugs yet proven to be effective against COVID-19. Drugs such as hydroxychloroquine and lopinavir/ritonavir have been shown to be ineffective. The antiviral drug remdesivir that was championed to beat the disease remained controversial due to the recent result of the interim report of Solidarity trial by WHO [Pan H et al., 2020; WHO, 2020b].

As more and more of these drugs failed to show benefit, researchers turn to vaccines as a potential solution for this pandemic [Pan H et al., 2020; Poland G et al., 2020; Siemieniuk R et al., 2020]. While potentially beneficial in preventing infection and inducing immunity in the population, there are many safety and ethical issues that need to be addressed when developing a vaccine. This is especially true as the urgent nature of this pandemic has driven many companies into a race for vaccine development. In this review, we would like to discuss important issues in COVID-19 vaccine development, their opportunities, hope, and challenges.

ADDRESS FOR CORRESPONDENCE:

Gatot Soegiarto, MD
Allergy and Clinical Immunology Division, Department of Internal Medicine Universitas Airlangga, Surabaya, Indonesia, Prof. Dr. Moestopo Street No 4-6, Surabaya 60286, Indonesia
Tel.: +628123547784
E-mail: gatotsby@yahoo.com; gatotsoegiarto@fk.unair.ac.id

PHASES OF CLINICAL TRIALS FOR VACCINE MANUFACTURING

The phases of vaccine development and medicine development in general can be divided into preclinical, clinical, and post-licensure studies. The preclinical phase of vaccine development consists of exploring vaccine candidate and testing it on animals or in vitro tissue or cell culture. Exploration of vaccine candidate requires extensive studies about pathogen biology. In this stage researchers look for potential antigen molecules, the genetic diversity of said molecules, and the demographic of infection. Multiple ways of pathogen evasion from the immune system and the mutation rate for each potential antigen are studied and taken into account to produce an effective vaccine candidate [Preiss S et al., 2016; Stern P, 2020]. The vaccine candidates are then tested unto animals or cell culture to study the safety, their ability to provoke an immune response i.e. their immunogenicity, and their efficacy in inducing protection [Preiss S et al., 2016; The College of Physicians of Philadelphia, 2020].

The clinical phase studies the safety and efficacy of the vaccine candidate in the human population. This usually consists of 3 phases. Phase I study usually involves fewer number of healthy people (<100) focuses on safety [Preiss S et al., 2016; Stern P, 2020]. Phase II study focuses on finding the dose, dosing frequency and establishing proof of immunogenicity. This phase usually involves hundreds of people, which include people that shared characteristics with the target population for the vaccine. Phase III is a large scale randomized controlled trial focusing on whether the vaccination dose and schedule have the desired clinical effect or not. At all phases, the safety profile and the adverse effect of the vaccine must be documented. After phase III, the vaccine can be submitted for licensure.

Currently, there are 213 vaccines for SARS-CoV-2 in development, 66 of which are undergoing clinical trial, and 9 of which are in phase III [Milken Institute, 2020].

Currently, there are 213 vaccines for SARS-CoV-2 in development, 66 of which are undergoing clinical trial, and 9 of which are in phase III [Milken Institute, 2020].

To overcome it is possible, due to the uniting the knowledge and will of all doctors in the world

The whole process of vaccine development until licensure generally takes around 10 to 30 years to complete [Preiss S et al., 2016; The College of Physicians of Philadelphia, 2020]. However, during pandemic situation such as now, economic and political conditions are pressuring the development of COVID-19 vaccine as fast as possible. This has resulted in fast-tracking of vaccine development, such as carrying out clinical trials without established preclinical phase, or combination of phase I and II concurrently [Jamrozik E, Selgelid M, 2020]. This has raised concern for the safety of the clinical trial participants.

This might also yield vaccines with marginal efficacy [Krause P et al., 2020]. To be able to yield herd immunity COVID-19 vaccine must be at least 50% protective to those who take it, and should be given to more than 70% of the population. A vaccine with 10-20% protection will produce a false sense of security that will cause more infection [Jamrozik E, Selgelid M, 2020; Milken Institute, 2020].

There are some issues that researchers need to keep in mind to ensure an effective and safe vaccine. First is the establishment of a clear correlate for protection and not just immunogenicity [Krause P et al., 2020]. It is clear that for some pathogens, e.g. Hepatitis C, serological conversion or the presence of circulating antibodies after administration of vaccine doesn't always correlate with clinical protection [Mauss S et al., 2014]. The same must be ascertained for COVID-19.

Clinical endpoint also needs to be defined. If the clinical endpoint is set to be protection from asymptomatic infection, the clinical trials might result in underestimating the value of the vaccine, that is a vaccine that gives some protection might be falsely assumed as not effective [Le T et al., 2020]. However, if the clinical endpoint is set to prevent very severe disease, the value of the vaccine might be overestimated, that is a vaccine that doesn't prevent enough transmission might be falsely assumed as effective because it reduces incidence of critical COVID-19 [Le T et al., 2020].

There are also problems in selecting the sample for the clinical trials. COVID-19 pandemic has affected almost all country in the world and trials using only samples from certain country might not apply to other countries where racial diversity, poverty, and malnutrition rate differ [Jeyanathan



M et al., 2020; Krause P et al., 2020; Stern P, 2020]. This is because the vaccine's efficacy is also influenced by the age, gender, ethnicity, and comorbidities of the recipients. Infants and elderly people, for example, are known to have a less robust immune reaction while showing more adverse effects [*Ciabattini A et al., 2018; Pichichero M, 2014*]. The children populations are particularly important to take note of. While it is true that children are less prone to get COVID-19 or to transmit it, this population still play some role in spreading infection [*Kelvin A, Halperin S, 2020; Li X et al., 2020*]. Few phase III trials include children as their participants, thus the effectivity and safety of the vaccines on these populations are less known [*Hodgson S et al., 2020; Hwang T et al., 2020*].

There are also some ethical issues especially in challenge trials where healthy people are purposefully infected with SARS-CoV-2. While such trials could potentially further accelerate vaccine development, health risk for participants and community should be considered [*Binik A, 2020; Evers D et al., 2015; Jamrozik E, Selgelid M, 2020*]. Researchers and health organizations should pay attention that the clinical trials do not violate the Declaration of Helsinki despite the urgent context of vaccine development [*WMA, 2018*].

VACCINE PLATFORMS FOR COVID-19

Vaccine platform is the vehicle used to deliver the pathogen's factors or properties which are expected to induce immune reaction from the host. In order to produce an effective vaccine more quickly and cheaply, the many COVID-19 vaccines now in development utilize vaccine platforms previously not available. These platforms have their own advantages and disadvantages; some are more efficacious or safe than others. The advantages and disadvantages of the vaccine platforms are summarized in table 1. More comprehensive list of COVID-19 vaccine in development can be found in the Milken Institute vaccine tracker [*Milken Institute, 2020*].

ATTENUATED VIRUS AND INACTIVATED VIRUS

Virus based vaccine consists of live virus or inactivated virus which is injected to the body of the host. Attenuation can be introduced by introducing mutations in key virulence factors, while inactivation of virus can be introduced by radiation, heating, or by chemical sterilization [*Kaur S, Gupta V, 2020; van Riel D, de Wit E, 2020*]. One disadvan-

tage of this method for COVID-19 is the requirement of SARS CoV-2 grown under Biosafety level 3(BSL3) (27-29). Regardless, three vaccines based on inactivated virus are going through clinical trials. One of these vaccines is the Sinovac vaccine which Indonesia is currently one of the locations for phase III testing [*Zhang Y et al., 2020*].

Protein-Based Vaccine

Protein-based vaccine consists of purified proteins obtained from the virus, cells infected with the virus, recombinant cells that express viral protein. This type of vaccine usually requires more adjuvant in order to be sufficiently immunogenic. New technologies such as the Baculovirus Expression Vector System, has given this platform new life. Currently, this platform is the most used in COVID-19 vaccine development [*Kaur S, Gupta V, 2020; Pandey S et al., 2020; van Riel D, de Wit E, 2020*]. Target molecules include receptor binding domain of S, E, M and N proteins of SARS-CoV-2 [*Adalja A et al., 2019; Kaur S, Gupta V, 2020; Pandey S et al., 2020; van Riel D, de Wit E, 2020*].

VIRUS VECTOR-BASED VACCINE

This type of platform uses a recombinant virus such which contain genes for the desired antigen. This vaccine platform was previously used for MERS-CoV and Ebola vaccine [*Kaur S, Gupta V, 2020; van Riel D, de Wit E, 2020*]. The virus used as vector can be non-replicative or replicative. Non-replicative vector only delivers its genome and lets the cell synthesize the desired antigen in order to induce an immune reaction. Replicative vector uses attenuated but infectious virus. It does what a non-replicative vector does and then replicate and infect another cell, thus resulting in more cells producing the desired antigen. This comes with a risk of developing mild infection and cellular abnormality due to insertion of the vector recombinant DNA to the gene [*Søborg C et al., 2009; Pandey S et al., 2020; Zhu F et al., 2020*].

DNA AND RNA BASED VACCINE

Nucleic acid based technology is widely used technology for COVID-19 vaccine, due to the relatively short time needed to develop [*Kaur S, Gupta V, 2020*]. The platform is also very safe to produce because it doesn't need handling of infectious material [*Kaur S, Gupta V, 2020; Pandey S et al., 2020*]. DNA or mRNA of the desired antigen is inserted into host cell and the gene expression ma-

TABLE I

Advantages and Disadvantages of Vaccine Platforms (26,28)

| Type of vaccine platform | Advantages | Disadvantages | Vaccine/Developer Example | Phase |
|------------------------------|---|---|--|--|
| Live attenuated virus | <ul style="list-style-type: none"> - High immunogenicity. - Usually doesn't require multiple doses | <ul style="list-style-type: none"> - Requires high biosafety level to produce - Risk of developing an infection, spontaneous recombination and mutation, reverting to more infectious state - Cannot be used for infants, pregnant, or immunocompromised people - Requires cold chain | <ul style="list-style-type: none"> - Indian Immunological Ltd (11) - CDX-005/ Codagenix, Serum Institute of India (11) | <ul style="list-style-type: none"> - Preclinical - Preclinical |
| Inactivated virus | <ul style="list-style-type: none"> - Less risk of developing infection nor spontaneous mutation - Has already been tested for previous viruses such as SARS CoV | <ul style="list-style-type: none"> - Requires high biosafety level to produce - Requires booster to maintain immunogenicity | <ul style="list-style-type: none"> - Sinovac/Institutio Butantan/Biofarma (30) - Wuhan Institute of Biology/Sinopharm (33) | <ul style="list-style-type: none"> - Phase III (NCT04582344, 669/UN6.KEP/EC/2020) - Phase III TR2000034780, NCT04560881) |
| Protein-based | <ul style="list-style-type: none"> - Rapid development due to new technology such as Baculovirus expression vector - Less adverse effect - Safe to produce | <ul style="list-style-type: none"> - Lower immunogenicity - Uncertain long-lasting protection | <ul style="list-style-type: none"> - Novavax, Emergent Biosolutions, Praha Vaccines (34) | <ul style="list-style-type: none"> - Phase III (EudraCT 2020-004123-16, NCT04583995) |
| Replicative viral vector | <ul style="list-style-type: none"> - Has a good history of use for MERS CoV - Safe to produce - The vector can act as adjuvant thus inducing good immune response | <ul style="list-style-type: none"> - The host might already have immunity against the vector, rendering it less effective for such population - Possible to induce antibodies to the viral vector and diminish the efficacy of the booster vaccine - Possible carcinogenesis due to vector DNA incorporation into host | <ul style="list-style-type: none"> - Institut Pasteur, Themis, University of Pittsburgh CVR, Merck Sharp & Dohme | <ul style="list-style-type: none"> - Phase I/II (NCT04497298, NCT04498247) |
| Non-replicating viral vector | <ul style="list-style-type: none"> - Safe to produce - Less adverse effect than replicative viral vector - The vector can act as adjuvant thus inducing good immune response | <ul style="list-style-type: none"> - No previous vaccine has been approved using this method - Less immunogenicity than replicative viral vector - The host might already have immunity against the vector, rendering it less effective for such population | <ul style="list-style-type: none"> - CanSino Biologics, Beijing Institute of Biology (32) - Gamaleya Research Institute (35) - AZD 1222 (formerly ChAdOx1)/Oxford University, AstraZeneca | <ul style="list-style-type: none"> - Phase III (NCT04566770, NCT04568811) - Phase III (NCT04564716, NCT04587219) - Phase III 06922165132) |
| DNA based | <ul style="list-style-type: none"> - Temperature stable - Simple, quick, and safe to produce - Cost-effective | <ul style="list-style-type: none"> - Some risk of recombination causing abnormality - Lower immunogenicity - Requires additional carrier or device to insert into cell | <ul style="list-style-type: none"> - INO-4800/Inovio Pharmaceuticals (36) | <ul style="list-style-type: none"> - Phase I/II (NCT04336410, NCT04447781) |
| mRNA based | <ul style="list-style-type: none"> - Simpler than DNA based vaccine to produce - Safe to produce - Cost effective | <ul style="list-style-type: none"> - Less stable than DNA based vaccine - Requires efficient carrier to insert into cell - Low immunogenicity | <ul style="list-style-type: none"> - mRNA1273/Moderna, National Institute of Health (37) - BNT162b2/BioNTec, Pfizer, Fosun Pharma (38) | <ul style="list-style-type: none"> - Phase III (NCT04470427) - Phase III (NCT04537949) |
| APC based | <ul style="list-style-type: none"> - Potential to induce cellular and humoral immune response | <ul style="list-style-type: none"> - Longer develop time - Requires cold chain - Requires more complicated administration to the host. | <ul style="list-style-type: none"> - aAPC Vaccine/ Shenzhen Genoimmune | <ul style="list-style-type: none"> - Phase I (NCT04299724) |

chinery of the host cell is expected to express the antigen, inducing an immune response. mRNA based vaccine is preferred over the DNA based because mRNA doesn't need crossing the nuclear membrane and thus faster in expression [van Riel D, de Wit E, 2020].

ANTIGEN PRESENTING CELL BASED VACCINE

This platform utilizes antigen presenting cells (APC), usually dendritic cells designed in vitro to present the desired antigen. The APCs are expected to induce cellular and humoral immunity in the host. This platform is not popular for COVID-19 due to the time needed to develop and multiple doses needed to induce effective immunity [van Riel D, de Wit E, 2020].

RACE FOR VACCINE AVAILABILITY

While multinational large companies are racing to produce a safe and effective vaccine, there is a concern that there wouldn't be enough vaccine produced for everybody. Developing countries fear that once vaccines are produced, they wouldn't have access to them. It is estimated that 67% of the total population (in Indonesia it translate to around 160 million people) need to be immune for herd immunity to develop. Therefore up scaling of vaccine production and equity of access for COVID-19 vaccine is very important to prevent resurgences of cases [Le T et al., 2020; Roush K, 2020].

One solution to this problem is a global partnership. In April 2020, WHO has launched Access to COVID-19 Tools (ACT) Accelerator, a global coalition that involves various philanthropist, scientist, research companies and health organization around the world. This coalition strives to not just accelerate vaccine's development but also upscale its production and ensure equitable access to COVID-19 tests, treatments, and vaccines [Hsu Y et al., 2020].

The "Solidarity Trial" held by WHO also helps to gather participants for clinical trials from around the world, especially from where the burden of this pandemic is large. While the primary purpose is to lower sampling bias, this also pushes for collaboration of lower-income countries paving the way for more equitable access for vaccines. The Solidarity Trial also facilitates the testing of multiple vaccines by using a pooled/common control, thus making the process more efficient [Krause P et al., 2020].

PASSIVE IMMUNIZATION/ADOPTIVE IMMUNITY

Passive or adoptive immunity can be achieved by using the sera of patients who recovered from COVID-19 (convalescent plasma therapy). Because it is believed to contain polyclonal antibodies directed to several natural epitopes of SARS-CoV-2, this approach had been tried in the management of COVID-19 patients as an empirical therapy [WHO, 2014]. It's consideration was based on the experiences in the past with SARS, MERS, H1N1-pandemic, measles, etc. [Cheng Y et al., 2005; Hung I et al., 2011; Ko J et al., 2018]. The efficacy of the convalescent plasma (CP) therapy is depended on its ability to antibody-neutralization of the virus, to opsonize the circulating virus in the blood, to accelerate the infected cells clearance, and to block the new infection.

The evaluation of several studies concerning the potential of CP as a therapeutic tool has been conducted [Ahn J et al., 2020; Duan K et al., 2020; Shen C et al., 2020; Zhang B et al., 2020]. Patients who involved in these studies usually were in critically ill condition, had many co-morbidities such as hypertension, cardiovascular disease, obesity, chronic kidney disease, or cerebrovascular diseases; they were all needed ICU admission for mechanical ventilation, or extracorporeal membrane oxygenation, or high-flow nasal cannula oxygenation. It has been shown that its administration for the critically ill patients led to the improvement of the clinical condition of almost all patients with reduced death rates. Patients in the treatment arm exhibited a significant difference in the clinical parameters (body temperature normalization, pulmonary lesions and ARDS resolution, weaning off the mechanical ventilation, etc.), laboratory parameters (levels of CRP, procalcitonin, IL-6) [Ahn J et al., 2020; Duan K et al., 2020; Zhang B et al., 2020]. There were also patients who experienced viral seroconversion after 7-37 days of CP therapy [Shen C et al., 2020]. The only problem for these studies is the lack of controlled or randomization of the study subjects, that impede the researchers to come to a conclusive statement. Further evaluation in clinical trials is needed and is currently ongoing [Yan X, 2020].

THE EXPECTED IMMUNE RESPONSE TOWARD THE VACCINES

As a major antigen, the S protein of SARS-CoV-2 is a potential target for the vaccine. The protein is located on the outer side of the virus and vital for the ability of viral infection. Previous studies using both SARS-CoV and SARS-CoV-2 also showed that antibodies against receptor-binding domain of S protein have strong neutralizing capacity [Jeyanathan M *et al.*, 2020]. Except for the D614G mutation, which now has become the most prevalent genotype, there seems to be low variation in the S protein [Duan L *et al.*, 2020; Jeyanathan M *et al.*, 2020]. It is no surprise that most vaccines in development use this molecule as their target.

In order to understand the expected immune response towards COVID-19 vaccination, some fundamental concept of natural infection with the virus must be appreciated. Firstly, SARS-CoV-2 infects cell through the interaction of the receptor-binding domain of the spike (S) protein with the angiotensinogen converting enzyme-2 (ACE2). Assistance from serine protease such as TMPRSS2 is needed [Duan L *et al.*, 2020; Jeyanathan M *et al.*, 2020]. Secondly, it seems that SARS-CoV-2 suppresses the innate immunity by a yet unknown mechanism. This can be seen from the low level of plasmacytoid dendritic cells, type 1 interferons, and the delay of activation of adaptive immunity by APCs in severe COVID-19 patients [Duan L *et al.*, 2020]. This suppression might also explain why elderly immunosenescent patients who have a weaker immune system have a more severe disease course [Duan L *et al.*, 2020; Jeyanathan M *et al.*, 2020; Poland G *et al.*, 2020]. The less robust innate antiviral response will cause a higher viral load which will overwhelm the adaptive immune system and provoke excessive secretions of cytokines in the later course of the disease.

Thirdly, SARS-CoV-2 also seems to inhibit the adaptive immunity, especially the Th1 response. This inhibition can be seen from the low level of CD8+ lymphocyte more prevalently seen in severe cases of COVID-19 [Jeyanathan M *et al.*, 2020; Poland G *et al.*, 2020]. The roles of Th2 and antibody-mediated immunity remain to be understood (Figure 1), as patients with mild or asymptomatic disease usually have lower antibody titer than those with severe disease [Jeyanathan M *et al.*,

2020; Poland G *et al.*, 2020]. However, this might also be attributed to higher viral load in severe diseases which induce a more pronounced Th2 response. However, it is still generally accepted that high neutralizing antibodies titer confers protection to the patients [Jeyanathan M *et al.*, 2020].

Vaccines against COVID-19, therefore, are expected to induce both innate and adaptive immune system in the host. Ideally, vaccines are expected to prime the innate immune system, inducing the so-called “trained immunity” by which immune response against future pathogen invasion is upregulated [Netea M *et al.*, 2020; Zhou R *et al.*, 2020]. Vaccines are also anticipated to provoke adaptive immunity, generating sufficient neutralizing antibodies that prevent interaction between the S protein and the ACE2 protein. More importantly, vaccines should ideally induce adaptive cellular immunity and generate enough CD8+ T lymphocytes, which will destroy infected cells [Jeyanathan M *et al.*, 2020; Poland G *et al.*, 2020]. All of these will result in reduction of the viral load and prevention of dysregulated cytokine secretions.

OPPORTUNITIES AND CHALLENGES

Overall, vaccines have a potential to end this pandemic. In the best-case scenario, an effective vaccine will stimulate long-lasting cellular and humoral immune response just by one injection. The generation of memory T cells will ensure CD8+ T cells that can kill virus-infected cells [Kaur S, Gupta V, 2020; Pandey S *et al.*, 2020; van Riel D, de Wit E, 2020]. The generation of memory B cells will ensure antibody with sufficient titers to neutralize and opsonize circulating virus [Kaur S, Gupta V, 2020; Pandey S *et al.*, 2020; Roush K, 2020; van Riel D, de Wit E, 2020].

However, on the other side, there are also risk that the vaccine might not work effectively against the virus. SARS-CoV-2 is an RNA virus which has a higher propensity for mutation. Mutation in targeted antigen will render a vaccine less effective. COVID-19 vaccines also use new platforms, some of which have undocumented safety profile [Le T *et al.*, 2020].

The possibility of antibody-dependent enhancement (ADE) must also be considered. In ADE the presence of non-neutralizing antibodies or antibodies at sub-neutralizing levels paradoxically will worsen the progression of the disease. The presence of antibodies against a virus will facili-

tate virus entry into macrophages through the FcγRII (Figure). Stable antibody-virus interaction will end up in virus destruction. However, in the case of weak binding from non-neutralizing antibodies, the virus can escape and replicate. These will result in higher viral titer and the release of more immune mediators such as IL-6 and IL-10 [Khandia R et al., 2018; Zaichuk T et al., 2020].

This phenomenon has been observed in multiple viruses such as Dengue virus, Zika Virus, SARS-CoV-1 and MERS-CoV [Khandia R et al., 2018; Lee W et al., 2020]. There are concerns that the new COVID-19 vaccines might induce ADE and cause a more severe disease such as the case with Dengvaxia in the Philippines recently [Bhopal S, Nielsen M, 2020]. However, it should be noted that




Figure 1. Vaccine-associated disease enhancement

Homologous SARS-CoV-2 infection will be blocked by neutralizing antibodies (Abs) resulted either from previous natural infection or vaccination. Heterotypic serotype virus infection might cause non-neutralization by the preexisting Abs. Vaccine-associated disease enhancement may occur through two different mechanisms, i.e. induction of non-neutralizing Abs or suboptimal concentration of neutralizing Abs, or Th2-biased immune response and immunopathology. Virus-antibody complexes bind to Fc receptor on the surface of immune cells such as monocyte-macrophage and dendritic cells. This will enhance virus uptake and viral load termed “antibody-dependent enhancement” (ADE) (a). The virus may evade the killing process and replicate within the cells and disseminate, or may induce the release of proinflammatory cytokines (b). Antigen-antibody complexes can also activate the complement pathway which further increase the inflammatory responses (c). Th2-biased immune response will induce the secretion of type 2 cytokines (IL4, IL-5, IL-13) as well as eosinophil chemoattractant, resulting in eosinophil infiltration and proinflammatory cytokine production in the lung. Moreover, the Th2 type immune response can lead to poor stimulation of Natural killer cells and CD8⁺ cytotoxic T lymphocytes (CTLs). Both events will result in unchecked viral replication and hyperinflammatory condition which eventually lead to acute lung injury or acute respiratory distress syndrome (d). This figure was redrawn and modified from Su S. and co-authors(62).

(fortunately) there has not been any report of ADE in the result of all phase I/II vaccine clinical trials, in trials using non-human primate, nor in clinical trials using convalescent plasma therapy [Lee W *et al.*, 2020; Wen J *et al.*, 2020]. There are much more to understand about the role of ADE in causing severe COVID-19. Currently, there haven't been any clinical feature nor biomarker that is useful to distinguish severe infection from ADE. Further research in this matter is surely needed [Arvin A *et al.*, 2020; Lee W *et al.*, 2020].

Although ADE seems to play a lesser role in causing severe COVID-19, previous experiences with vaccine-associated disease enhancement such as RSV, SARS CoV, and Dengue vaccines could still teach us valuable lessons (Figure) [Bhopal S, Nielsen M, 2020; Su S *et al.*, 2020]. The vaccine should be able to induce high titer of neutralizing antibody since subpar concentration of antibody might induce ADE such with the case of Dengue and SARS CoV vaccine [Bhopal S, Nielsen M, 2020; Su S *et al.*, 2020]. Th2-biased response should be avoided as it is more associated with severe disease both in RSV and COVID-19. This can be done by avoiding adjuvants that are associated with Th2 activation such as alum and instead using Th1-biased adjuvants [Bhopal S, Nielsen M, 2020; Su S *et al.*, 2020].

Finally, the acceptance of the general public is also a concern. The general population is scared about the safety of the vaccine in this hastened

state of development. One study in Israel reported that only 75% of the general population is willing to be vaccinated for COVID-19. At the same time, only 78% of doctors and 61% of nurses are willing to be vaccinated [Dror A *et al.*, 2020]. The people's trust and confidence in researchers and health professionals play an important role in reducing this vaccine hesitancy. Health professionals and researchers should maintain good communication and assure the people that the highest safety and efficacy standards are being used in this accelerated vaccine development [Bhopal S, Nielsen M, 2020; Dror A *et al.*, 2020]. For this reason, the Coalition for Epidemic Preparedness Innovations and other organizations had held a scientific working meeting on March 2020 to discuss about the designs of the vaccine that will reduce the safety concerns and recommend the desired animal models and assessment of the immunologic response in phases of clinical trials to determine the dimension of the risk [Lambert P *et al.*, 2020].

As COVID-19 continues to be a global threat, a safe and effective vaccine can be one of the greatest weapons to finally end this pandemic. However, many uncertainties about the efficacy, safety, equitability, and public acceptance of the vaccine remain. With the development of many vaccines entering phase III, we hope that these uncertainties be answered with satisfactory result.

Acknowledgement: The author wish to acknowledge the help of Michael Austin Pradipta Lusida, MD regarding the language editing and proofread of the final manuscript.

REFERENCES

1. Adalja A, Watson M, Cicero A, Inglesby T. *Vaccine platforms: state of the field and looming challenges*. Center for Health Security. Johns Hopkins University. 2019; 1-24
2. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH., *et al.* Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. *J Korean Med Sci.* 2020; 35(14): e149
3. Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R., *et al.* A perspective on potential antibody-dependent enhancement of SARS-CoV-2. *Nature.* 2020; 584(7821): 353-363
4. Bhopal S, Nielsen M. *Vaccine hesitancy in low- and middle-income countries: potential implications for the COVID-19 response*. *Arch Dis Child.* 2020; <https://doi.org/10.1136/archdischild-2020-318988>
5. Binik A. *What risks should be permissible in controlled human infection model studies?* *Bioethics.* 2020; 34(4): 420-430
6. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK., *et al.* Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol.* 2005; 24(1): 44-46

7. Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medagliani D. Vaccination in the elderly: The challenge of immune changes with aging. *Semin. Immunol.* 2018; 40: 83-94
8. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrahi M., et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol.* 2020; 35(8): 775-779
9. Duan K, Liu B, Li C, Zhang H, Yu T., et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci. U. S. A.* 2020; 117(17): 9490-9496
10. Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. *Front Immunol.* 2020; 11: 576622
11. Evers DL, Fowler CB, Mason JT, Mimmall RK. Deliberate microbial infection research reveals limitations to current safety protections of healthy human subjects. *Sci Eng Ethics.* 2015; 21(4): 1049-1064
12. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. *Lancet Infect Dis.* 2020; [https://doi.org/10.1016/S1473-3099\(20\)30773-8](https://doi.org/10.1016/S1473-3099(20)30773-8)
13. Hsu YC, Wu HC, Hsu YF, Chen PY, Chiang JR. Covid-19: Global Progress in Developing Vaccines and Mechanisms for Equitable Distribution. *Epidemiol. Bull.* 2020; 36(16): 95
14. Hung IF, To KK, Lee CK, Lee KL, Chan K., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis an Off. Publ Infect Dis Soc Am.* 2011; 52(4): 447-456
15. Hwang TJ, Randolph AG, Bourgeois FT. Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19). *JAMA Pediatr.* 2020; 174(9): 825-826
16. Jamrozik E, Selgelid MJ. COVID-19 human challenge studies: ethical issues. *Lancet Infect Dis.* 2020; 20(8): e198-e203
17. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD., et al. Immunological considerations for COVID-19 vaccine strategies. *Nat Rev Immunol.* 2020; 20(10): 615-632
18. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. *Virus Res.* 2020; 288: 198114
19. Kelvin AA, Halperin S. COVID-19 in children: the link in the transmission chain. *Lancet. Infect. Dis.* 2020; 20(6): 633-634. [https://doi.org/10.1016/S1473-3099\(20\)30236-X](https://doi.org/10.1016/S1473-3099(20)30236-X)
20. Khandia R, Munjal A, Dhama K, Karthik K, Tiwari R., et al. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. *Front Immunol.* 2018; 9: 597
21. Ko JH, Seok H, Cho SY, Ha YE, Baek JY., et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. *Antivir Ther.* 2018; 23(7): 617-622
22. Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R., et al. COVID-19 vaccine trials should seek worthwhile efficacy. *Lancet (London, England).* 2020; 396(10253): 741-743
23. Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB., et al. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. *Vaccine.* 2020; 38(31): 4783-4791
24. Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. *Nat Rev Drug Discov.* 2020; 19(10): 667-668
25. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nat. Microbiol.* 2020; 5(10): 1185-1191
26. Li X, Xu W, Dozier M, He Y, Theodoratou E. The role of children in transmission of SARS-CoV-2: A rapid review. *J Glob Health.* 2020; 10(1): 11101
27. Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Kamps BS. *Hepatology-A clinical textbook.* 2014; flying publisher. Retrieved from <https://www.hepatologytextbook.com/>

28. Milken Institute. COVID-19 Treatment and Vaccine Tracker. 2020; Retrieved October 29, 2020, from https://milkeninstitute.org/sites/default/files/2020-03/Covid19_Tracker_WEB.pdf
29. Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J, Curtis N, van Crevel R., et al. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. *Cell*. 2020; 181(5): 969-977
30. Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM., et al. Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results. *MedRxiv*. *N Engl J Med*. 2020; NEJMoa2023184. doi: 10.1056/NEJMoa2023184
31. Pandey SC, Pande V, Sati D, Upreti S, Samant M. Vaccination strategies to combat novel corona virus SARS-CoV-2. *Life Sci*. 2020; 256: 117956
32. Pichichero ME. Challenges in vaccination of neonates, infants and young children. *Vaccine*. 2014; 32(31): 3886-3894
33. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. *Lancet (London, England)*. 2020; 396(10262): 1595-1606
34. Preiss S, Garçon N, Cunningham AL, Strugnell R, Friedland LR. Vaccine provision: Delivering sustained & widespread use. *Vaccine*. 2016; 34(52): 6665-6671
35. Roush K. The Race to Develop a COVID-19 Vaccine. *Am J Nurs*. 2020; 120(10): 14-15
36. Shen C, Wang Z, Zhao F, Yang Y, Li J., et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA*. 2020; 323(16): 1582-1589
37. Siemieniuk RAC, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A., et al. Drug treatments for covid-19: living systematic review and network meta-analysis. *BMJ*. 2020; 370: m2980
38. Søbørg C, Mølbak K, Doherty TM, Ulleryd P, Brooks T., et al. Vaccines in a hurry. *Vaccine*. 2009; 27(25-26): 3295-3298
39. Stern PL. Key steps in vaccine development. *Ann. Allergy, Asthma Immunol. Off. Publ. Am. Coll. Allergy, Asthma, Immunol*. 2020; 125(1): 17-27
40. Su S, Du L, Jiang S. Learning from the past: development of safe and effective COVID-19 vaccines. *Nat Rev Microbiol*. 2020; 1-9
41. The College of Physicians of Philadelphia. Vaccine Development, Testing, and Regulation. 2020; Retrieved October 26, 2020, from <https://www.historyofvaccines.org/content/articles/vaccine-development-testing-and-regulation>
42. van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. *Nat Mater*. 2020; 19(8): 810-812
43. Wen J, Cheng Y, Ling R, Dai Y, Huang B., et al. Antibody-dependent enhancement of coronavirus. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020; 100: 483-489
44. WHO (a). Coronavirus Disease (COVID-19) Situation Reports. 2020; Retrieved October 25, 2020, from <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
45. WHO (b). Solidarity clinical trial for COVID-19 treatments. 2020; Retrieved November 20, 2020, from <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments>
46. WHO (c). WHO Coronavirus Disease (COVID-19) Dashboard. 2020; Retrieved October 25, 2020, from https://covid19.who.int/?gclid=Cj0KCQjwxNT8BRD9ARIsAJ8S5xaXoDY5I3Our8WIDdNCTbcvj03BMhsqF4ug4mVodcFyRYXrLFUpMSsaAr07EALw_wcB
47. WHO. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks: interim guidance for national health authorities and blood transfusion services. 2014; Retrieved October 30, 2020, from <https://www.who.int/publications/i/item/WHO-HIS-SDS-2014.8>
48. WMA. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. 2018; Retrieved October 27, 2020, from <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>
49. Yan X. Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19). 2020; Retrieved October 30, 2020, from <http://www.chictr.org.cn/showprojen.aspx?proj=49544>.

-
50. Zaichuk TA, Nechipurenko YD, Adzhubey AA, Onikienko SB, Chereshev VA., et al. *The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector.* *Mol Biol.* 2020; 1-15
51. Zhang B, Liu S, Tan T, Huang W, Dong Y., et al. *Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.* *Chest.* 2020; 158(1): e9-e13
52. Zhang YJ, Zeng G, Pan HX, Li CG, Kan B., et al. *Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial.* *MedRxiv.* 2020; <https://doi.org/10.1101/2020.07.31.20161216>
53. Zhou R, To KKW, Wong YC, Liu L, Zhou B., et al. *Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.* *Immunity.* 2020; 53(4): 864-877.e5
54. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ., et al. *Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.* *Lancet (London, England).* 2020; 395(10240): 1845-1854



Source details

New Armenian Medical Journal

Scopus coverage years: from 2009 to 2021

Publisher: World Glaucoma Association

ISSN: 1829-0825

Subject area: Medicine: General Medicine

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

CiteScore 2020

0.3



SJR 2020

0.141



SNIP 2020

0.150



[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology



CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. [Learn more >](#)

CiteScore 2020

$$0.3 = \frac{70 \text{ Citations 2017 - 2020}}{220 \text{ Documents 2017 - 2020}}$$

Calculated on 05 May, 2021

CiteScoreTracker 2021

$$0.4 = \frac{85 \text{ Citations to date}}{221 \text{ Documents to date}}$$

Last updated on 06 March, 2022 • Updated monthly

CiteScore rank 2020

| Category | Rank | Percentile |
|------------------|----------|------------|
| Medicine | | |
| General Medicine | #637/793 | 19th |

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)



←

Ads by Google

Stop seeing this ad Why this ad? ⓘ

New Armenian Medical Journal

| | | | |
|-------------------------------------|--|------------------------------|--|
| COUNTRY Armenia | SUBJECT AREA AND CATEGORY Medicine ↳ Medicine (miscellaneous) | PUBLISHER UNIPRINT | H-INDEX <h1>5</h1> |
| PUBLICATION TYPE Journals | ISSN 18200254, 18290825 | COVERAGE 2009-2020 | INFORMATION Homepage namj.ysmu@gmail.com |

SCOPE

Information not localized

Join the conversation about this journal


Quartiles




FIND SIMILAR JOURNALS

options

| | | | | |
|--|--|---|---|---|
| 1 Journal of Investigative Medicine USA 53% similarity | 2 Biomedical papers of the Medical Faculty of the CZE 50% similarity | 3 Medicine (United States) USA 50% similarity | 4 American Journal of the Medical Sciences USA 50% similarity | 5 Medicina CHE 49% similarity |
|--|--|---|---|---|





Leave a comment

Name

Email
(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.